This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: For those who can tolerate it, I think they're likely going to get a bispecific in the academic center, but some patients can't. And a treatment like Zinlanta with a cleaner safety profile and also very fast action, you know, very fast time to assess response is critical for those patients. But also, the majority of patients are going to progress post-bispecific. So also in the fourth-line setting, that starts to open up as well. So there's clearly a place for Zinlanta in the academic setting. It's going to be less than what it was before, and we knew that was going to happen, which is why our strategy has been to adjust the model to capitalize on the bigger opportunity, which is growth in the community.
spk00: Great. Thank you so much. That was very helpful. Thank you.
spk02: Thank you. There are no further questions at this time, and I will now turn the call back to Amit.
spk01: Well, I just want to thank everyone for joining. Thanks for your interest in the company, and thanks for joining the quarterly update. We look forward to keeping you updated on our progress, and I hope everyone has a great day. Thank you.
spk02: This concludes our program, and you may now disconnect. Thank you.
Disclaimer